CONFIDENTIAL

The $32 Billion Windfall

Fellow Investor,

A small biotech company possesses a non-invasive colon cancer screening test that could make colonoscopies obsolete.

It works by identifying abnormal cells in stool samples that patients can collect in the privacy of their homes.

All with no special diets or laxatives to clear your system.

In a clinical trial that screened 10,000 people, this company’s screening test found more cancer cases than another commonly used test, the fecal immunochemical blood test.

What’s more, The New England Journal of Medicine also found that it identified more precancerous growths than any other test as well.

So it’s no surprise the company’s year-over-year quarterly sales have skyrocketed 172% while its stock price has jumped 500% over the past two years.

And it’s all because the cost of its test is nearly FIVE TIMES less than that of a colonoscopy—$650 vs. $3,000.

For this reason, you’re going see Health Maintenance Organizations (HMOs) require doctors to prescribe this simple test in lieu of scheduling a colonoscopy.

You need only do the math to understand why: the potential savings from this company’s breakthrough test is a whopping $2,350 per screening!

When you figure 14 million colonoscopies are performed each year, the savings from this company’s test could be as much as $32 billion.

This is why I think this company is going to make millionaires out of its early shareholders.

Imagine the disruption in the colonoscopy market as doctors prescribe tens of thousands of these screening tests in lieu of colonoscopies. That would be comparable to the way Tesla revolutionized the electric car market or Netflix revolutionized video streaming.

But you’ll need to move quickly here.

With the company’s stock price rising 500% in two years, seven top analysts giving the company a STRONG BUY rating, and 10 top institutions investing over $1 billion, word is starting to leak out.

If you can get in at today’s low prices, you could easily see your money double in the next two years. Hold longer term—five to 10 years—and you could easily see a $10,000 investment grow well into $100,000.

Don’t Let This Opportunity Pass You By!

The company possesses the same profit profile that’s doubled our readers’ money 29 times in 47 years, including a number of breakout winners like these:

  • American Medical, +639%
  • Archer Daniels, +100%
  • Beech Aircraft, +270%
  • WD-40, +173%
  • MCI Communications, +240%
  • General Public Utilities, +151%
  • SafeCard, +206%
  • Triangle Industries, +112%
  • Amazon, +1,290%
  • American Power Conv., +1,075%
  • Ascend Communications, +440%
  • Home Depot, +239%
  • JDS Uniphase, +387%
  • Qualcomm, +559%
  • Summit Technology, +443%
  • Yahoo, +316%
  • Apple, +746%
  • Crocs, +307%
  • eResearch, +257%
  • Expedia, +105%
  • First Solar, +415%
  • Net Ease, +200%
  • TASER, +296%
  • XM Satellite Radio, +396%

My Expectation: A Big Jump on
Earnings and a Double in the Next Twelve Months

With our time-proven technical indicators forecasting a MAJOR BREAKOUT ahead for this biotech juggernaut; this is not an opportunity you want to sit on now.

In order to help you get in, I’ve put together a special report titled The $32 Billion Windfall that will give you all the details on this company, including its name and stock symbol.

This report is yours, absolutely free. All I ask is that you give my Cabot Growth Investor investment research advisory service a risk-free try.

Remember, the report will give you all the details on the biotech company that’s about to see its profits skyrocket as more and more HMOs require this company’s colon cancer screening test in lieu of a colonoscopy.

Your free report will only be the beginning of an incredible financial windfall. That’s because Cabot Growth Investor will bring you …

The Same Market-Beating Advantage That’s
Doubled Investors’ Money 29 Times in 47 Years

In a world where hundreds of financial investing advisories come and go yearly, Cabot Growth Investor has stood the test of time.

Not only delivering 47 years of profitable investing advice but also doubling our readers’ money 29 times along the way—all thanks to our time-proven technical system our founder, Carlton Lutts, created in 1980.

You’ll find nothing is easier, simpler or more profitable.

That’s the beauty of our time-proven, momentum-based technical system. That’s because it not only scientifically identifies for you the big breakout growth stocks before they take off …

… but then automatically compounds your wealth by reinvesting your profits in new ground-floor opportunities, like these …

  • XM Satellite Radio; +396%
  • JDS Uniphase; +387%
  • Qualcomm; +559%
  • Summit Technology; +443%
  • Yahoo; +316%
  • Apple; +746%
  • Crocs; +307%
  • eResearch; +257%
  • Expedia; +105%
  • First Solar; +415%
  • NetEase; +200%
  • TASER; +296%

As a result, Cabot Growth Investor has become one of the most respected, trusted, and profitable investment advisories in America and why thousands of Americans trust us to help them safely, securely and systematically build their wealth.

That’s why we’ve made it possible for you to receive a free copy of The $32 Billion Windfall along with the opportunity to test-drive Cabot Growth Investor for the next 30 days risk-free.

That way you can see for yourself how our profits stack up on all our recommendations without your risking a dime.

Here’s the Best Part: Your Profits Are Always Guaranteed.

When we started our advisory in 1970, we promised our readers that we would do everything within our power to make certain our clients would profit from our advice, or they would not pay a dime.

Over the past 47 years, we’ve kept to that commitment by offering an unheard-of 100% money-back GUARANTEE.

This means that if you’re not impressed and delighted with the profits you gain from our recommendations, just let me know and I’ll always send you a full 100% refund during your 30-day risk-FREE trial.

We hold nothing back.

You may think that I’m sticking my neck out making a guarantee like this. I’m not really.

After all, the Cabot Growth Investor is one of a handful of newsletters that have been published for over four decades. When you deliver what you promise, people stick with you.

Once you see everything, we believe you will too.

Here at Cabot, our mission has always been not only to bring independent investors the most profitable and practical investment advice on the planet but also to bring it to you at the most affordable price.

Over the years, I’m proud to say we’ve kept that commitment on both counts. Not only doubling investors’ money 29 times in 47 years but also at a price ALL INVESTORS can afford—$1.36 a day. ($497)

That $1.36 a day price includes twice-monthly issues, a private website and email and text alerts, plus these five additional reports:

  • The $32 Billion Windfall
  • Ten Rules for Big Profits in Growth Stocks
  • 10 Rising Superstar Stocks for the Next 6 Months
  • Seven Ways to Build and Protect Your Wealth
  • Six Ways to Pick Monster Growth Stocks

Naturally, I couldn’t offer you such a strong guarantee if I didn’t believe that Cabot Growth Investor would deliver as promised. With our 47-year track record for building wealth, I know you won’t be disappointed.

So why not join us and test-drive Cabot Growth Investor on my dime before you make a final decision?

With our 100% money-back guarantee, that’s quite a bargain, considering you can cancel at any time during the first 30 days and get all your money back.

This is how Cabot Growth Investor has become one of the most respected and profitable investment advisories on Wall Street.

Click Here Now to Get the Name of This Small Biotech
Stock Sent Directly to Your Inbox Free

If it’s just 1/10th as profitable as our biggest winners, you’ll grab 50% gains every six months or so and may never invest any other way again.

But you’ll need to hurry.

  1. Waiting until after the company declares earnings could make it impossible for you to get it at my buy below price.
  2. Grabbing it now will give you a head start in the race for profits—long before earnings come out and Wall Street bids this one higher.

So what are you waiting for?

✓ Download your FREE copy of the $32 billion windfall.

✓ Check out the explosive profits our recommendations can bring you.

✓ Take FULL advantage of my 100% satisfaction guarantee to decide if Cabot Growth Investor is for you.

And then decide.

To make sure you don’t miss this opportunity to grab our biotech doubler before it doubles again, now IS the time to join us.

With my money-back guarantee, you have nothing to lose and everything to gain.

Click here now to get started.

Mark my words: Once you grab your first 50% gain, I’ll bet I couldn’t pry your subscription from your hand if I tried.

Begin here now.

I guarantee it will be one of the most profitable investing decisions of your investing life or your money will be promptly refunded.

Click here to join today.

Welcome Aboard,

mikecintolo

 

 

Mike Cintolo
Chief Analyst, Cabot Growth Investor

P.S. Remember—by simply saying yes today you’ll not only be able to test drive Cabot Growth Investor for the next 30 days … but also be able to lock in our lowest price.

So what are you waiting for?

When you order now, you’ll find out the name of our Biotech Doubler that could jump 50% on earnings and begin your trial subscription immediately.